4D Molecular Therapeutics (FDMT) Operating Leases (2021 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Operating Leases of $15.0 million for Q1 2026, down 17.19% year-over-year from $18.2 million in Q1 2025, and down 4.88% quarter-over-quarter from $15.8 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Operating Leases (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Operating Leases for 6 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 17.19% year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $15.0 million (down 17.19% YoY), while the FY2025 annual figure was $15.8 million, down 16.6% from the prior year.
- Operating Leases declined to $15.0 million in Q1 2026 per FDMT's latest filing, from $15.8 million in the prior quarter.
- Across five years, Operating Leases topped out at $19.7 million in Q3 2024 and bottomed at $10.5 million in Q2 2024.
- Historically, Operating Leases has averaged $14.6 million across 5 years, with a median of $14.4 million in 2022.
- Annual changes were most pronounced in 2025 — Operating Leases surged 65.93% — and 2026, when it slipped 17.19%.
- 4D Molecular Therapeutics' Operating Leases stood at $13.5 million in 2022, then declined by 14.46% to $11.5 million in 2023, then surged by 64.63% to $19.0 million in 2024, then fell by 16.6% to $15.8 million in 2025, then decreased by 4.88% to $15.0 million in 2026.
- Business Quant data shows FDMT's Operating Leases at $15.0 million in Q1 2026, $15.8 million in Q4 2025, and $16.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.26 Mn |
| Mar 31, 2026 | 15.05 Mn |
| Dec 31, 2025 | 15.82 Mn |
| Sep 30, 2025 | 16.57 Mn |
| Jun 30, 2025 | 17.36 Mn |
| Mar 31, 2025 | 18.17 Mn |
| Dec 31, 2024 | 18.97 Mn |
| Sep 30, 2024 | 19.74 Mn |
| Jun 30, 2024 | 10.46 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Dec 31, 2023 | 11.52 Mn |
| Sep 30, 2023 | 12.03 Mn |
| Jun 30, 2023 | 12.53 Mn |
| Mar 31, 2023 | 13.01 Mn |
| Dec 31, 2022 | 13.47 Mn |
| Sep 30, 2022 | 13.92 Mn |
| Jun 30, 2022 | 14.40 Mn |
| Mar 31, 2022 | 14.78 Mn |
| Dec 31, 2021 | 15.22 Mn |